This is an oral medication in capsule form.
*Release of Zeposia
: As the country’s healthcare system is dealing with the unprecedented COVID-19 pandemic, Bristol Myers Squibb has made the decision to postpone the release of Zeposia, which they believe to be in the best interest of their patients, customers, and employees. They will continue to monitor the environment and partner with the healthcare community to determine when Zeposia will be made available.
Zeposia® is a sphingosine 1-phosphate receptor modulator, which is thought to act by retaining certain white blood cells (lymphocytes) in the lymph nodes, thereby preventing those cells from crossing the blood-brain barrier into the central nervous system (CNS). Preventing the entry of these cells into the CNS reduces inflammatory damage to nerve cells.
Zeposia was approved by the U.S. Food and Drug Administration (FDA) for treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.
to read the Zeposia Prescribing Information for healthcare professionals.
to read the Zeposia Medication Guide for patients.
SupportBristol Myers Squibb
Financial Assistance Program
Financial assistance program information has not been released and will be published here when it is available.